Single-Vial PSMA Ligand Radiolabeling with Stabilizer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an optimized method to label PSMA binding ligands with 68Ga, 67Ga, or 64Cu for imaging prostate cancer tumors that ensures rapid, efficient, robust, and safe procedures with high radiochemical purity for intravenous injection.
Innovation Solution
A method involving a single vial containing a PSMA binding ligand, a buffering agent, sodium chloride, and a stabilizer against radiolytic degradation, where a radioactive isotope solution is added and incubated to achieve labeling, with optional pH adjustment, resulting in a radiolabeled PSMA binding ligand suitable for PET/CT or SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If a multi-step labeling procedure is used, then the radiochemical purity can be improved, but the procedure time and complexity increase
Solution Approach 1:
The patent combines multiple labeling steps into a single-vial procedure. The kit contains pre-combined components (PSMA ligand, buffering agent, stabilizer) in one vial, allowing the radioactive isotope to be added and incubated in a single step, achieving high radiochemical purity without requiring multiple separate operations.
Solution Approach 2:
The buffering agent and stabilizer are pre-added to the vial before the labeling reaction. This preliminary preparation ensures optimal conditions for radiolabeling are already in place, eliminating the need for time-consuming adjustments during the actual labeling process and enabling rapid achievement of high radiochemical purity.
2Productivity
If a single vial procedure is used, then the procedure time is reduced, but the radiochemical purity may be compromised
Solution Approach 1:
The patent optimizes the composition parameters of the single-vial kit, including the types and amounts of buffering agents and stabilizers, to create conditions that enable high radiochemical purity to be achieved within a short incubation time. The specific formulation allows the labeling reaction to proceed efficiently to completion in one step.
Solution Approach 2:
The buffering agent and stabilizer act as intermediaries that facilitate the radiolabeling reaction. The buffering agent maintains optimal pH for the chelation reaction, while the stabilizer prevents radiolytic degradation, both enabling high radiochemical purity to be achieved in the simplified single-vial procedure.
3Stability of the object's composition
If stabilizers are added to prevent radiolytic degradation, then the stability of the labeled compound is improved, but the solution complexity increases
Solution Approach 1:
The stabilizer is combined with the PSMA ligand and buffering agent in a single vial formulation. This integration means the stabilizer is already present in the correct concentration and location, providing protection against radiolytic degradation without requiring separate addition steps or complex handling procedures.
Solution Approach 2:
The stabilizer in the kit formulation automatically provides protection against radiolytic degradation during the labeling process and in the final radiopharmaceutical solution. This self-protecting formulation eliminates the need for additional stabilization steps or complex external protection systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides high radiochemical purity of the labeled compound, with radiochemical purity of at least 91% and minimal free or non-complexed radioactive species, ensuring effective imaging while maintaining stability and safety.
Implementation Method 1
labeling a PSMA binding ligand with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu
Implementation Method 2
a stabilizer against radiolytic degradation, preferably gentisic acid
Data Source
AI summary
The present invention relates to methods for labeling a PSMA binding ligand with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu, said method comprising the steps of: i. providing a single vial comprising, in dried form, said PSMA binding ligand f the following formula (I): (I) at least one buffering agent, sodium chloride and a stabilizer against radiolytic degradation, ii. adding a solution of said radioactive isotope into said single vial, thereby obtaining a solution of said PSMA binding ligand of formula (I) with said radioactive isotope, iii. mixing the solution obtained in ii., and incubating it for a sufficient period of time for obtaining said PSMA binding ligand labelled with said radioactive isotope, and, iv. optionally, adjusting the pH of the solution.